Sarilumab and tocilizumab are equally effective in reducing organ support duration and death in patients who are critically ill with COVID-19.

The approval was supported by pooled data from 2 open-label, single arm trials: the phase 2 NI-0501-06 study and the phase 3 EMERALD trial.

Dr. Kimberly Trotter distilled four high-impact disease clusters—gout, rheumatoid arthritis (RA), systemic lupus ...

Monoclonal antibodies and other new agents to treat RA will undoubtedly be available in the future. Which patients will benefit from these agents?

Severance Hospital recently achieved 3,000 cases of auditory implant surgery. The process by which a person hears sounds goes through the outer ear (outside the ear), the middle ear (echoic and ...

Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even ...

Background: Tumour necrosis factor α blockers in rheumatoid arthritis are known to increase the risk of serious infections defined as life-threatening, requiring hospitalisation or intravenous ...

Background: Anakinra treatment has been reported to be effective in some patients with systemic-onset juvenile idiopathic arthritis (SoJIA) or adult-onset Still disease (AoSD). Objectives: To assess ...

This summary of a Cochrane review presents what we know from research about the side effects of biologics used for many conditions including inflammatory arthritis and other inflammatory conditions, ...